# Contact RegenLife Peptides — Editorial Desk

> Reach the RegenLife Peptides editorial desk regarding citations, corrections, or research-related correspondence about our Recovery & Tissue Repair research peptide briefing.

Correspondence on citations, corrections, and newly published research — the briefing this desk is built to keep current.

## Editorial correspondence

RegenLife Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published study on BPC-157, GHK-Cu, TB-500, or GHK, or a regulatory update that changes an approval or anti-doping status. This class of correction is the most useful message this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected or challenged, and the supporting reference — a DOI or PubMed identifier wherever possible. That format allows a proposed change to be verified against its source before it is acted on.

**Editorial mailbox:** editors@regenlifepeptides.com

## What this desk cannot do

So no message goes unanswered for the wrong reason: RegenLife Peptides is a literature briefing, not a clinical service or product vendor. It cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a finding from a cited study applies to a specific person's situation, or sell, source, or help locate any compound from any supplier. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.

---

A clinician's-briefing digest on tissue-repair research peptides — read it for citations, not for a treatment plan.